ClinicalTrials.gg
Active, not recruitingNCT00339495Updated Nov 17, 2026

Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial

An observational study in Cancer and Death, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Open to participants aged 55 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by National Cancer Institute (NCI) · Observational

How we know

Updated Nov 17, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
154,900
Ages
55 Years to 74 Years
Sex
All
01

Study summary

The Division of Cancer Preventionl (DCP, formerly DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). In 1996 the NCI Executive Committee approved the expansion of the PLCO Trial to collect additional materials and to conduct additional studies. About, 74,000 men and 74,000 women, aged 55-74 years, have been randomized on a 50/50 basis into screening or usual care arms. Additional blood is collected from screened subjects and saliva for buccal cells from control subjects. Pathologic tissues are obtained for selected cases that develop cancer or selected related diseases (e.g. colon polyps, benign prostatic hyperplasia). Additional questionnaire-based risk and disease-related information is also collected, withconfirmation of disease status from medical records. Genetic, biochemical and questionnairebasedrisk information will be related to the development of cancer and other diseases in this population. Volunteers who provide samples for these studies will not routinely receive their individual results from the Additional Investigation. Subjects requesting such information, however, will be provided their test results. In 2009 the NCI Executive Committee approved the Extended Follow-up of subjects beyond the original 13-year follow-up period. Participants will be reconsented for the release of records to a single NCI-Designated Central Data Collection Center (CDCC), which will administer the annual mailings containing the annual study update questionnaire and a brief (1-2 page) risk factor questionnaire. Individuals who do not consent to release their identifiers to the CDCC will be followed up passively through linkage to state cancer registries and the National Death Index.

This protocol Review Application is for (1) the collaboration of intramural scientists in the Division of Cancer Epidemiology and Genetics (DCEG) in the Additional Studies and (2) the coordination, in collaboration with DCP, of the Extended Follow-up.

Read the detailed description

The Division of Cancer Preventionl (DCP, formerly DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). In 1996 the NCI Executive Committee approved the expansion of the PLCO Trial to collect additional materials and to conduct additional studies. About, 74,000 men and 74,000 women, aged 55-74 years, have been randomized on a 50/50 basis into screening or usual care arms. Additional blood is collected from screened subjects and saliva for buccal cells from control subjects. Pathologic tissues are obtained for selected cases that develop cancer or selected related diseases (e.g. colon polyps, benign prostatic hyperplasia). Additional questionnaire-based risk and disease-related information is also collected, with confirmation of disease status from medical records. Genetic, biochemical and questionnaire-based risk information will be related to the development of cancer and other diseases in this population. Volunteers who provide samples for these studies will not routinely receive their individual results from the Additional Investigation. Subjects requesting such information, however, will be provided their test results. In 2009 the NCI Executive Committee approved the Extended Follow-up of subjects beyond the original 13-year follow-up period. Participants will be reconsented for the release of records to a single NCI-Designated Central Data Collection Center (CDCC), which will administer the annual mailings containing the annual study update questionnaire and a brief (1-2 page) risk factor questionnaire. Individuals who do not consent to release their identifiers to the CDCC will be followed up passively through linkage to state cancer registries and the National Death Index.

This protocol Review Application is for (1) the collaboration of intramural scientists in the Division of Cancer Epidemiology and Genetics (DCEG) in the Additional Studies and (2) the coordination, in collaboration with DCP, of the Extended Follow-up.

02

Conditions studied

  • Cancer
  • Death

Browse trials for

Keywords

  • Prostate
  • Screening Trial
  • Ovarian
  • Lung
  • Colorectal
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 154,900 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Community samples from ten US screening centers: Birmingham AL, Denver CO, Detroit MI, Honolulu HI, Marshfield WI, Minneapolis MN, Pittsburgh PA, Salt Lake City UT, St Louis MO, and Washington DC

Eligibility criteria

  • INCLUSION CRITERIA:

Men and women aged 55-74 years who do not have a prior history of PLCO tumors and have not undergone routine screening.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
154,900 participants (actual)

Groups and cohorts

  • Non-Screening

    Participants received their usual care

  • Screening

    Participants received trial-provided screening examinations for prostate, lung, colorectal, and ovarian cancer

06

What researchers measure

Primary outcomes

  1. Death

    Death

    Time frame: Extended beyond T13

  2. Cancer incidence

    Cancer Incidence

    Time frame: Extended beyond T13

07

Study locations

1 site
  • Westat, Inc.
    Rockville, Maryland 20850, United States
08

References and documents

Publications

  • Zhang T, Moore SC, Fu S, Albanes D, Liao LM, Loftfield E, Playdon MC, Weinstein SJ, Yu K, Stolzenberg-Solomon RZ. Metabolomic profiling of genotype-derived ABO blood group, secretor status, and Lewis antigens and association with pancreatic ductal adenocarcinoma risk. Am J Epidemiol. 2026 Jun 3;195(6):1572-1584. doi: 10.1093/aje/kwag055. PubMed 41804787 ↗
  • Malcomson FC, Shams-White MM, Reedy J, Huang WY, Moore SC, Loftfield E. Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trial. BJC Rep. 2025 Nov 19;3(1):81. doi: 10.1038/s44276-025-00195-6. PubMed 41261199 ↗
  • Yang Y, Wang Y, Wu H, Geyer NR, McDonald AC, Wang M. Dietary Fiber Intake and Prostate Cancer Outcomes and All-Cause Mortality: Findings From a Secondary Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Study. J Acad Nutr Diet. 2025 Nov;125(11):1718-1729. doi: 10.1016/j.jand.2025.07.003. Epub 2025 Jul 18. PubMed 40684909 ↗
  • Wei W, Wang S, Yuan Z, Ren Y, Wu J, Gao X, Wang R, Li J. Plant-based diets and the risk of lung cancer: a large prospective cohort study. Eur J Nutr. 2025 Feb 1;64(2):73. doi: 10.1007/s00394-024-03570-0. PubMed 39891747 ↗
  • Jiang Y, Xie Q, Chen R. Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results From a Prospective Cohort Study. Clin Breast Cancer. 2022 Feb;22(2):e206-e213. doi: 10.1016/j.clbc.2021.06.010. Epub 2021 Jun 26. PubMed 34548240 ↗
  • Wang K, Wu Q, Li Z, Reger MK, Xiong Y, Zhong G, Li Q, Zhang X, Li H, Foukakis T, Xiang T, Zhang J, Ren G. Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study. Clin Nutr. 2021 May;40(5):3370-3378. doi: 10.1016/j.clnu.2020.11.009. Epub 2020 Nov 16. PubMed 33277073 ↗
  • Makkar R, Butt J, Huang WY, McGlynn KA, Koshiol J, Pawlita M, Waterboer T, Freedman ND, Murphy G. Seropositivity for Helicobacter pylori and hepatobiliary cancers in the PLCO study. Br J Cancer. 2020 Sep;123(6):909-911. doi: 10.1038/s41416-020-0961-0. Epub 2020 Jun 29. PubMed 32595210 ↗
  • Kunzmann AT, Coleman HG, Huang WY, Berndt SI. The association of lifetime alcohol use with mortality and cancer risk in older adults: A cohort study. PLoS Med. 2018 Jun 19;15(6):e1002585. doi: 10.1371/journal.pmed.1002585. eCollection 2018 Jun. PubMed 29920516 ↗
  • Playdon MC, Ziegler RG, Sampson JN, Stolzenberg-Solomon R, Thompson HJ, Irwin ML, Mayne ST, Hoover RN, Moore SC. Nutritional metabolomics and breast cancer risk in a prospective study. Am J Clin Nutr. 2017 Aug;106(2):637-649. doi: 10.3945/ajcn.116.150912. Epub 2017 Jun 28. PubMed 28659298 ↗
  • Piper MR, Freedman DM, Robien K, Kopp W, Rager H, Horst RL, Stolzenberg-Solomon RZ. Vitamin D-binding protein and pancreatic cancer: a nested case-control study. Am J Clin Nutr. 2015 Jun;101(6):1206-15. doi: 10.3945/ajcn.114.096016. Epub 2015 Apr 22. PubMed 25904602 ↗
09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 1998 to primary completion in Feb 2020, 261 months.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's 261 months is above that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Feb 2020, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2006
First posted
Jun 21, 2006
StartActual
May 1, 1998
Primary completionActual
Feb 28, 2020was Dec 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Feb 28, 2020 (actual)
Nov 17, 2026
Show all 3 updates
  1. Nov 17, 2026
    Primary completion Dec 31, 2026→Feb 28, 2020 (now actual)
  2. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 2, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00339495
Responsible party
Sponsor
First posted
Jun 21, 2006
Start date
May 1, 1998
Primary completion
Feb 28, 2020
Completion
Dec 31, 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Steven C Moore, Ph.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion